Lamotrigine-induced Stevens-Johnson syndrome.
OBJECTIVE
A case of lamotrigine-induced Stevens-Johnson syndrome (SJS) is reported.


CONCLUSIONS
A 29-year-old woman with a medical history of schizoaffective disorder arrived at the emergency department with a severe generalized skin reaction. Three to four days prior she had noticed bumps on her lips that had spread to her oral mucosa. She had also developed a diffuse, erythematous, pruritic full-body rash involving the palms of her hands and the soles of her feet and began to feel feverish. Her medications at admission included aripiprazole 30 mg p.o. daily, escitalopram 10 mg p.o. daily, and lamotrigine 75 mg p.o. daily. Lamotrigine was the only new medication, initiated four weeks before this admission. The dermatology service confirmed the diagnosis of SJS using punch biopsy. Lamotrigine was suspected to be the culprit and was discontinued immediately. The patient was given oral prednisone 40 mg and intravenous fluids. Hydroxyzine was given for pruritus, and petroleum jelly and viscous lidocaine were applied to her lips. On hospital day 2, her symptoms and dermatological manifestations improved, but she continued to complain about irritation and slight pain of the mouth. She then received a mouthwash consisting of diphenhydramine, viscous lidocaine, and sodium bicarbonate. On hospital day 3, the patient had improved substantially and was discharged home. Reports of these dermatological reactions in patients receiving lamotrigine for the treatment of bipolar disorder are limited. Dosing, prompt recognition, and patient education are crucial for preventing morbidity and mortality associated with the development of serious cutaneous reactions.


CONCLUSIONS
SJS was associated with lamotrigine use, despite appropriate dosing and dosage adjustment.
Hilas
Olga
O
Clinical Pharmacy Practice, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.
Charneski
Lisa
L
D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D009519:New York City; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced*; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects*
D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine